A Study of Telemonitoring in Cancer Patients

Launched by CENTRE HOSPITALIER DE BLIGNY · Apr 19, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help cancer patients during their treatment. It compares the usual care that patients receive in-person with a digital tool called Cureety that allows for telemonitoring. This means that some patients will get their regular care along with the added support of tracking their health through an app, while others will just receive the usual in-person care. The goal is to see if using this app can reduce the number of phone calls patients need to make during the first four months of their cancer treatment.

To participate in this study, you need to be at least 18 years old and starting treatment for cancer at the Centre Hospitalier de Bligny. You should be able to use a smartphone and have internet access, as the Cureety app will be used for monitoring your health. Participants will fill out questionnaires about their quality of life and satisfaction with care at the start of the trial and after two and four months. This study is recruiting patients now, and your involvement could help improve care for future cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients that have provide written informed consent for study participation.
• • 2. Patients aged 18 years or older.
• • 3. Patients initiating oral or intravenous treatment (chemotherapy, immunotherapy, targeted therapies etc.) for localized or metastatic or recurrent cancer treated at the CH Bligny.
• • 4. Patients with the capacity, personally (e.g., language and capacity to use the application), and in terms of infrastructure (internet access, possessing a smart phone etc.) to perform telemonitoring with Cureety.
• • 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
• Exclusion Criteria:
• • Patients treated for cancer at the CH Bligny in the last 5 years